We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+11.56%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.04B
AUM Growth
-$6.31M
Cap. Flow
-$151M
Cap. Flow %
-7.43%
Top 10 Hldgs %
59.49%
Holding
43
New
9
Increased
11
Reduced
3
Closed
11

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$160M
2
SHPG
Shire pic
SHPG
+$151M
3
BMY icon
Bristol-Myers Squibb
BMY
+$80.4M
4
NUVA
NuVasive, Inc.
NUVA
+$60.9M
5
TSRO
TESARO, Inc.
TSRO
+$56.3M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$159M
2
BIVV
Bioverativ Inc. Common Stock
BIVV
+$59.1M
3
VTRS icon
Viatris
VTRS
+$53.3M
4
RDUS
Radius Health, Inc.
RDUS
+$31.8M
5
THC icon
Tenet Healthcare
THC
+$29.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SHPG
1
DELISTED
Shire pic
SHPG
$164M 8.07%
+1,100,000
New +$151M
NKTR icon
2
Nektar Therapeutics
NKTR
$2.41B
$159M 7.83%
100,000
-123,333
-55% -$159M
AGN
3
DELISTED
Allergan plc
AGN
$143M 7.02%
850,000
+250,000
+42% +$41.9M
BIIB icon
4
Biogen
BIIB
$30.7B
$141M 6.92%
+515,000
New +$160M
HCA icon
5
HCA Healthcare
HCA
$85.7B
$121M 5.95%
1,250,000
– –
EVHC
6
DELISTED
Envision Healthcare Holdings Inc
EVHC
$110M 5.38%
2,850,000
+350,000
+14% +$13.1M
THC icon
7
Tenet Healthcare
THC
$21.8B
$103M 5.06%
4,250,000
-1,500,000
-26% -$29.9M
TSRO
8
DELISTED
TESARO, Inc.
TSRO
$98.6M 4.84%
1,725,000
+875,000
+103% +$56.3M
UHS icon
9
Universal Health Services
UHS
$9.88B
$92.4M 4.53%
780,000
– –
BMY icon
10
Bristol-Myers Squibb
BMY
$132B
$79.1M 3.88%
+1,250,000
New +$80.4M
GHDX
11
DELISTED
Genomic Health, Inc.
GHDX
$76.9M 3.78%
2,458,100
– –
MDCO
12
DELISTED
Medicines Co
MDCO
$65.9M 3.23%
2,000,000
+400,000
+25% +$12.5M
ATRA icon
13
Atara Biotherapeutics
ATRA
$73.6M
$63.1M 3.1%
64,668
+43,248
+202% +$39.4M
NUVA
14
DELISTED
NuVasive, Inc.
NUVA
$62.7M 3.08%
+1,200,000
New +$60.9M
GSK icon
15
GSK
GSK
$104B
$58.6M 2.88%
1,200,000
– –
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$58M 2.85%
1,200,000
+400,000
+50% +$22.3M
AMAG
17
DELISTED
AMAG Pharmaceuticals
AMAG
$53.4M 2.62%
2,650,000
– –
VTRS icon
18
Viatris
VTRS
$20.7B
$51.5M 2.53%
1,250,000
-1,250,000
-50% -$53.3M
MYGN icon
19
Myriad Genetics
MYGN
$507M
$44.3M 2.18%
1,500,000
– –
BKD icon
20
Brookdale Senior Living
BKD
$3.49B
$43.6M 2.14%
6,500,000
– –
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
$43.6M 2.14%
825,000
+225,000
+38% +$13.1M
ELGX
22
DELISTED
Endologix Inc
ELGX
$39.3M 1.93%
930,000
+130,000
+16% +$5.58M
PRGO icon
23
Perrigo
PRGO
$1.43B
$33.3M 1.64%
+400,000
New +$34.9M
CSII
24
DELISTED
Cardiovascular Systems, Inc.
CSII
$27.1M 1.33%
+1,236,360
New +$29.7M
KTWO
25
DELISTED
K2M Group Holdings, Inc
KTWO
$25.6M 1.26%
1,349,323
+499,323
+59% +$9.89M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Camber Capital Management held 43 positions worth $2.04B, down 0.31% from $2.04B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Camber Capital Management withdrew a net $151M in Q1 2018, closing 11 positions and reducing 3 holdings. Its most notable exit was Bioverativ Inc. Common Stock, an estimated $59.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 62% a quarter earlier.

Against the trend, Camber Capital Management opened a new position in Biogen worth $141M.

  • Camber Capital Management's largest Q1 2018 buy was Biogen: 515,000 shares worth $141M.
  • Camber Capital Management added most to TESARO, Inc. in Q1 2018, an estimated $56.3M increase.
  • Camber Capital Management's biggest Q1 2018 reduction was Nektar Therapeutics, cutting an estimated $159M.
  • Camber Capital Management fully exited Bioverativ Inc. Common Stock in Q1 2018, selling an estimated $59.1M.
  • Camber Capital Management's ten largest holdings make up 59% of its $2.04B portfolio in Q1 2018.
  • Camber Capital Management opened 9 new positions and closed 11 in Q1 2018.
  • Camber Capital Management's portfolio value fell 0.31% quarter-over-quarter to $2.04B.

Based on Camber Capital Management's 13F filing for Q1 2018, filed 15 May 2018.